Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emerging Market Rx Growth Heating Up As Mature Markets Cool, IMS Says

This article was originally published in PharmAsia News

Executive Summary

The improving regulatory environment in emerging international markets is helping to drive global pharmaceutical growth despite a slowdown within mature markets

You may also be interested in...

Global Generics Market Shows Significant Decline Despite Higher Volumes and Double Digit Growth In Japan, Europe – IMS Health

MUMBAI - Despite a robust increase in volumes, the global generics prescription market has grown by just 3.6 percent, a nearly 7 percent drop from the 11.4 percent growth seen in 2007, a report by IMS Health, the global pharmaceutical and health care intelligence provider said

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts